SCHEMBL24102447

SCHEMBL24102447

CC(=O)O[C@H]1CCC2C3C([C@@H](C)C[C@@]21C)[C@H]1CCC(=O)C=C1C[C@H]3C

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 6/20 0.72
▸ PGR P06401 5/20 0.46
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ NR3C2 P08235 2/20 0.40
▸ SERPINA6 P08185 2/20 0.39
▸ ESR1 P03372 2/20 0.37
▸ SHBG P04278 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ BRCA1 P38398 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP17A1 P05093 1/20 0.37
▸ SLC22A1 O15245 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25863725 1.00 AR (0.72) ARPGRMAPTLMNANR3C2
SCHEMBL12355440 1.00 AR (0.72) ARPGRMAPTLMNANR3C2
SCHEMBL25863727 1.00 AR (0.72) ARPGRMAPTLMNANR3C2
SCHEMBL24102425 0.92 AR (0.72) ARPGRMAPTLMNANR3C2
SCHEMBL13125416 0.91 AR (0.70) ARPGRMAPTLMNANR3C2
SCHEMBL5030883 0.91 AR (0.70) ARPGRMAPTLMNANR3C2
SCHEMBL3452466 0.91 AR (0.70) ARPGRMAPTLMNANR3C2
SCHEMBL25863524 0.90 AR (0.78) ARPGRMAPTLMNANR3C2
SCHEMBL25863522 0.90 AR (0.78) ARPGRMAPTLMNANR3C2
SCHEMBL25863641 0.90 AR (0.84) ARPGRMAPTLMNANR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-07-20 — — US disclosed
WO-2021252761-A2 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME SHBG, CYP19A1, GNRHR AR 7/4885PGR 16/4885MAPT 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback